MyoKardia appoints David Meeker, MD to Board of directors

MyoKardia appoints David Meeker, as M.D to the Company’s board of directors.

Dr. Meeker is executive VP and head of Sanofi Genzyme, the specialty care global business unit of Sanofi that focuses on rare diseases, multiple sclerosis, oncology, and immunology.  Dr. Meeker joined Genzyme in 1994 and held positions of increasing responsibility including VP, medical affairs, chief operating officer and ultimately president and CEO.

Prior to joining Genzyme, Dr. Meeker was director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at The Ohio State University. Dr. Meeker received his M.D. degree from the University of Vermont Medical School. He completed the Advanced Management Program at Harvard Business School in 2000.

CEo Tassos Gianakakos said that he is thrilled to welcome David to their board at such an important time for MyoKardia. David’s commitment to patients with debilitating and neglected diseases has been a hallmark throughout his career. He look forward to his expertise and guidance at MyoKardia as we make progress towards our mission of changing the lives of people with serious cardiovascular diseases.